Patents Examined by Nianxiang Zou
-
Patent number: 11819535Abstract: There is described herein methods of treating a disease associated with extracellular matrix (ECM) in a patient. In some cases, the methods comprise administering to the patient a therapeutically effective amount of fibroblasts which express CD36.Type: GrantFiled: June 14, 2019Date of Patent: November 21, 2023Assignee: UNIVERSITY HEALTH NETWORKInventors: Fei-Fei Liu, Xiao Zhao, Kenneth W. Yip
-
Patent number: 11813329Abstract: A method for treating or reducing the incidence of recurrence of cancer, benign tumors, or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC and basal-cell carcinoma, by administering one or more doses of HPV recombinant vaccine to a patient.Type: GrantFiled: October 12, 2020Date of Patent: November 14, 2023Assignee: HPVVAX, LLCInventors: Tim Ioannides, Evangelos V. Badiavas
-
Patent number: 11807676Abstract: The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors. Furthermore, the invention relates to the use of MHC-Ia open conformers as immunomodulators, particularly in diseases where the interaction to diverse immunoregulatory receptors such as KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRB2, and PTPRJ modulates an immune response, and in diseases were the negative modulation of Tregs is a therapeutic strategy, e.g. infectious diseases.Type: GrantFiled: March 7, 2022Date of Patent: November 7, 2023Assignees: UNIVERSITÄT ZÜRICH, UNIVERSITÄT BASELInventors: Osiris Marroquin Belaunzaran, Christoph Renner
-
Patent number: 11806432Abstract: Embodiments of the present invention provide for novel compositions and methods for making and using a thermally stable human papilloma virus (HPV) formulation or other stabilized multimeric virus formulation. Certain embodiments concern lyophilizing HPV formulations in the presence or absence of adjuvants. Other embodiments concern lypophilizing HPV capsomere vaccines in order to increase stability of an immunogenic composition against HPV infection for storage, delivery and use. In yet other embodiments, a single immunogenic composition can include a thermally stable formulation of multiple virus serotypes. Yet other embodiments disclosed herein concern multi-targeted antigen complexes lyophilized in formulations of use to prolong stability and/or enhance immunogenicity. Other embodiments concern exposing lyophilized multi-targeted antigen complexes to elevated temperatures to enhance immunogenicity of the antigens of the complex to multiple pathogens.Type: GrantFiled: February 4, 2022Date of Patent: November 7, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventors: Theodore Randolph, Robert Garcea
-
Patent number: 11801298Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.Type: GrantFiled: September 10, 2021Date of Patent: October 31, 2023Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
-
Patent number: 11793869Abstract: The present invention is directed to improved methods of Enterovirus inactivation by formaldehyde in presence of tromethamine buffer resulting in maximum recovery of D-antigen. Subsequent adsorption of said sIPV on aluminium hydroxide provides significantly dose reduced sIPV compositions.Type: GrantFiled: October 10, 2019Date of Patent: October 24, 2023Assignee: Serum Institute Of India Pvt Ltd.Inventors: Rajeev Mhalasakant Dhere, Sambhaji Shankar Pisal, Jagdish Kamalaji Zade, Rajendra Narayan Sabale, Hitesh Kumar Malviya, Sunil Mahor, Chetan Vilasrao Joshi
-
Patent number: 11786458Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: GrantFiled: May 24, 2022Date of Patent: October 17, 2023Assignee: ENA RESPIRATORY PTY LTDInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Patent number: 11788157Abstract: Disclosed herein are DNA amplification methods for quantifying DNA fragments of a target DNA in a sample by size. This can be used, for example, to detect tumor-derived viral DNA in blood sample and distinguish it from larger viral DNA from non-tumor sources. In particular, disclosed herein are methods of detecting, monitoring or treating a human papilloma virus (HPV)-associated malignancy in a subject that involves detecting a presence or absence of at least one circulating tumor-derived HPV DNA in a sample from the subject. Kits for accomplishing the same are also provided.Type: GrantFiled: November 8, 2021Date of Patent: October 17, 2023Assignee: The University of North Carolina at Chapel HillInventors: Gaorav Gupta, Bhishamjit S. Chera, Sunil Kumar
-
Patent number: 11789020Abstract: Provided herein are diagnostic methods, devices and kits for detecting neutralizing antibodies to SARS-CoV-2.Type: GrantFiled: May 12, 2021Date of Patent: October 17, 2023Assignee: Sapphire Biotech, Inc.Inventors: Sergei Svarovsky, Douglas Lake, Alim Seit-Nebi, Maria González-Moa
-
Patent number: 11773142Abstract: Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).Type: GrantFiled: December 11, 2018Date of Patent: October 3, 2023Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Dan H. Barouch, Peter Abbink, Mark Justin Iampietro, Menzo J. E. Havenga
-
Patent number: 11773153Abstract: The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular, allergies, infectious disease, diabetes, hyperproliferative disorders and/or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.Type: GrantFiled: October 29, 2021Date of Patent: October 3, 2023Assignee: Immunomic TherapeuticsInventor: Teri Heiland
-
Patent number: 11744885Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.Type: GrantFiled: May 14, 2021Date of Patent: September 5, 2023Assignee: Inovio Pharmaceuticals, Inc.Inventors: Stephanie Ramos, Jewell Walters, Jian Yan, Anna Slager, Charles Reed, Kate Broderick
-
Patent number: 11732012Abstract: Provided is a modified matrix protein of a vesicular stomatitis virus, wherein the protein has amino acid substitutions at position 21, position 51, position 111 and position 221. Further provided are an attenuated strain of the vesicular stomatitis virus producing the modified matrix protein, a composition containing the attenuated strain, and uses thereof in preparing a drug for killing abnormally proliferating cells, inducing and promoting antitumor immune response, or eliminating immunosuppression in a microenvironment of a tumor tissue.Type: GrantFiled: September 24, 2020Date of Patent: August 22, 2023Assignee: FANTASIA BIOPHARMA (ZHEJIANG) CO. LTD.Inventors: Frank XiaoFeng Qin, Jing Xia
-
Patent number: 11730803Abstract: A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.Type: GrantFiled: February 25, 2022Date of Patent: August 22, 2023Assignees: CASE WESTERN RESERVE UNIVERSITY, TRUSTEES OF DARTMOUTH COLLEGEInventors: Nicole F. Steinmetz, Amy M. Wen, Steven Fiering, Patrick H. Lizotte
-
Patent number: 11717567Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.Type: GrantFiled: March 8, 2021Date of Patent: August 8, 2023Assignee: Baylor Research InstituteInventors: SangKon Oh, Sandra Zurawski, Gerard Zurawski
-
Patent number: 11707495Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.Type: GrantFiled: January 24, 2020Date of Patent: July 25, 2023Assignees: Boehringer Ingelheim International GmbH, ViraTherapeutics GmbHInventors: Philipp Mueller, Klaus Erb, Patrik Erlmann, Tobias Friederike Nolden, John Edward Park, Guido Wollmann
-
Patent number: 11697676Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.Type: GrantFiled: January 6, 2021Date of Patent: July 11, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Christian S. Hinrichs, Steven A. Rosenberg
-
Patent number: 11696947Abstract: The present invention relates i.a. to an H52 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said H52 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.Type: GrantFiled: October 28, 2019Date of Patent: July 11, 2023Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Annika Kraemer-Kuehl, Egbert Siegfried Mundt, Hans-Christian Philipp
-
Patent number: 11690905Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods.Type: GrantFiled: April 9, 2021Date of Patent: July 4, 2023Assignee: The Rockefeller UniversityInventors: Jeffrey V. Ravetch, Taia Wang, Jad Mamaary
-
Patent number: 11684637Abstract: Disclosed are engineered oncolytic viruses, related fusion proteins and polynucleotides encoding them, and methods for treating cancer using the engineered viruses. In one aspect, disclosed herein are engineered oncolytic viruses, wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor.Type: GrantFiled: May 25, 2018Date of Patent: June 27, 2023Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.Inventors: Griffith Parks, Alicja Copik